Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls-Reference-Cited by-同舟云学术

Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls

Published:2022-04 Issue:4 Volume:32 Page:271-283
ISSN:0960-8966
Container-title:Neuromuscular Disorders
language:en
Short-container-title:Neuromuscular Disorders

Author:

Muntoni Francesco,Signorovitch James,Sajeev Gautam,Goemans Nathalie^ORCID,Wong Brenda^ORCID,Tian Cuixia,Mercuri Eugenio,Done Nicolae^ORCID,Wong Hallee,Moss Jackson,Yao Zhiwen,Ward Susan J.,Manzur Adnan,Servais Laurent,Niks Erik H.^ORCID,Straub Volker,de Groot Imelda JM,McDonald Craig

Publisher

Elsevier BV

Subject

Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health

Reference51 articles.

1. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions;Wu;Pharmacoepidemiol Drug Saf,2020

2. FDA approves first treatment for a form of Batten disease,2017

3. Drug approval package: Myozyme (Alglucosidase Alfa),2006

4. The use of external controls in FDA regulatory decision making;Jahanshahi;Ther Innov Regul Sci,2021

5. Viewpoint: randomised controlled trials using invasive ‘placebo’ controls are unethical and should be excluded from Cochrane Reviews;Cyna;Cochrane Database Syst Rev,2011

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Becker Muscular Dystrophy: Could Altering the Natural History of Decline Help Tackle Unmet Medical Need?;European Medical Journal;2023-12-14

2. 269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy – What have we learned? 9–11 December 2022, Hoofddorp, The Netherlands;Neuromuscular Disorders;2023-11

3. First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD;Nature Medicine;2023-10

4. Tamoxifen in children with Duchenne muscular dystrophy;The Lancet Neurology;2023-10

5. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR);Annals of Neurology;2023-09-07